Get the Stockscreener App
15.68
1.82%
-0.29
After Hours:
15.68
Monte Rosa Therapeutics Inc stock is traded at $15.68, with a volume of 736.01K.
It is down -1.82% in the last 24 hours and down -3.03% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$15.97
Open:
$15.86
24h Volume:
736.01K
Relative Volume:
0.68
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-7.00
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
-11.11%
1M Performance:
-3.03%
6M Performance:
+247.67%
1Y Performance:
+125.94%
1-Day Range:
$15.66
$16.23
1-Week Range:
$15.66
$17.61
52-Week Range:
$3.5001
$19.17
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
15.68 | 1.04B | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6.4%Here's Why - MarketBeat
Monte Rosa Therapeutics (GLUE) price target increased by 22.54% to 21.78 - MSN
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 4.8%Here's Why - MarketBeat
Squarepoint Ops LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Wedbush Remains a Buy on Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to S&P Biotechnology Select Industry Index - marketscreener.com
Is Monte Rosa Therapeutics Inc. stock supported by innovation pipelineOptions Play & AI Forecasted Entry/Exit Points - Улправда
Monte Rosa Therapeutics (GLUE) Price Target Increased by 22.54% to 21.78 - Nasdaq
How Monte Rosa Therapeutics Inc. stock reacts to inflationary pressuresGlobal Markets & Momentum Based Trading Ideas - Улправда
What margin trends mean for Monte Rosa Therapeutics Inc. stockJuly 2025 Setups & Community Verified Watchlist Alerts - Улправда
First Week of GLUE February 2026 Options Trading - Nasdaq
Price Action: How institutional buying supports Monte Rosa Therapeutics Inc. stock2025 Analyst Calls & Fast Gaining Stock Strategy Reports - DonanımHaber
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa reports positive phase 1/2 study results - MSN
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6%Here's Why - MarketBeat
Assessing Monte Rosa Therapeutics After Its 162.4% Surge and DCF Implied Upside in 2025 - Yahoo Finance
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of "Hold" by Brokerages - MarketBeat
Monte Rosa Therapeutics announces data from Phase 1/2 study of MRT-2359 - Yahoo Finance
Wells Fargo upgrades Monte Rosa Therapeutics (GLUE) - MSN
Wells Fargo Upgrades Monte Rosa Therapeutics (GLUE) - Nasdaq
GSPT1 chat favorable as Monte Rosa scores in prostate phase I/II - BioWorld MedTech
Why Is Monte Rosa Stock Trading Higher Today? - Benzinga
Monte Rosa reports promising results for MRT-2359 in prostate cancer - Investing.com Nigeria
Wedbush Adjusts Monte Rosa Therapeutics Price Target to $26 From $19, Maintains Outperform Rating - marketscreener.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Sets New 52-Week HighShould You Buy? - MarketBeat
Monte Rosa Therapeutics (GLUE) Receives Analyst Upgrade and Pric - GuruFocus
Monte Rosa Therapeutics Says Advanced Prostate Cancer Combination Therapy Trial Shows 64% Disease Control - marketscreener.com
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Adjusts Price Target to $22 From $13 - marketscreener.com
Monte Rosa Reports Positive Phase 1/2 Study Results - TipRanks
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - Investing News Network
Monte Rosa Therapeutics : Corporate Presentation – December 2025 - marketscreener.com
Monte Rosa Therapeutics Announces Positive Interim Data for MRT-2359 in Prostate Cancer - TradingView — Track All Markets
Monte Rosa Therapeutics (NASDAQ: GLUE) posts positive MRT-2359 Phase 1/2 data - Stock Titan
Monte Rosa Therapeutics announces compelling clinical activity of MRT-2359 in combination with enzalutamide - marketscreener.com
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - The Manila Times
Monte Rosa Therapeutics to Host Conference Call on Interim Results of MRT-2359 for mCRPC Treatment - Quiver Quantitative
Monte Rosa (Nasdaq: GLUE) to share MRT-2359 mCRPC Phase 1/2 data Dec. 16 - Stock Titan
Franklin Resources Inc. Raises Stock Holdings in Monte Rosa Therapeutics, Inc. $GLUE - Defense World
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - sharewise.com
GLUE Crosses Above Average Analyst Target - Nasdaq
Critical Survey: Monte Rosa Therapeutics (NASDAQ:GLUE) & Cogent Biosciences (NASDAQ:COGT) - Defense World
Piper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics stock hits 52-week high at $16.66 By Investing.com - Investing.com India
Monte Rosa Therapeutics stock hits 52-week high at $16.66 - Investing.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
Monte Rosa Therapeutics (GLUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Improved Revenues Required Before Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock's 26% Jump Looks Justified - 富途牛牛
Monte Rosa: Looking Mispriced After Big Pharma Validation (NASDAQ:GLUE) - Seeking Alpha
Monte Rosa Therapeutics Jumps 124.9% in 2025 But Are Investors Getting Ahead of Themselves - Yahoo Finance
Hillsdale Investment Management Inc. Makes New $271,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):